Clinical Trials Logo

Clinical Trial Summary

The program is to provide access to an experimental drug called pozelimab and to document the long-term safety of pozelimab in patients with Protein-Losing Enteropathy (PLE). CD55-deficient PLE/CHAPLE disease is a rare inherited disease of the immune system. This can be a life-threatening condition that is usually found when patients are children.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06003881
Study type Expanded Access
Source Regeneron Pharmaceuticals
Contact Requests for compassionate use must be initiated by a treating p
Phone +44(0) 1932 824 100
Email medicineaccess@clinigengroup.com
Status Available
Phase

See also
  Status Clinical Trial Phase
Completed NCT04209634 - Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) Phase 2/Phase 3